Recently, patient blasts, documented by NGS as bearing complements of Flt3ITD with IDH2/WT1/TET2/DNMT3A mutations (when alone or in mutually nonexclusive pairs), were also tested in vitro for proliferative silencing /apoptosis by Bortezomib with Flt3 inhibitor, and we found efficacy and synergy of the combination in these mutational binary- or ternary-defined subgroups in Flt3ITD+ve AML (HS Boswell, in preparation). Here, TET2 is linked to acute myeloid leukemia.